Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2

Full article: Future therapeutic treatment of COPD: Struggle between oxidants and cytokines

Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2

Lihu Yang's research works Merck & Co., Whitehouse Station (MSD) and other places

Targeting lung inflammation: novel therapies for the treatment of COPD. - Abstract - Europe PMC

Structural Analysis of Chemokine Receptor-Ligand Interactions. - Abstract - Europe PMC

The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities

Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview

Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2

Full article: Chemokine receptor antagonists: Part 1

Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview

Philadelphia, PA, August 22-26, 2004 - ACS Division of Medicinal

The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities

Full article: Future therapeutic treatment of COPD: Struggle between oxidants and cytokines